

Affibody® Imaging Agent, Negative Control

BACKGROUND

This Affibody® molecule binds to a protein of bacterial origin. It does not bind to human HER2 or EGFR. Cross reactivity with other species has not been tested.

Affibody® Imaging Agent, Negative Control (denoted Z03638) is an engineered variant of the Taq Polymerase binder Z01155, where 11 amino acid in the scaffold have been changed in order to resemble the Affibody® Imaging Agents.

The Affibody® Imaging Agent, Negative Control is modified with a unique C-terminal cysteine for directed single-point chemical modification, facilitating labeling to thiol reactive reagents such as various fluorescent dyes.

Affibody® products are supplied for research use only and may not be used in a manufacturing process or in manufactured products or in human subjects. The Affibody® products shall in no event be used in medical or clinical applications, unless otherwise expressly stated by Affibody. The purchaser of Affibody® products is solely liable to ensure compliance with any regulatory requirements related to the purchaser's use of Affibody® products.

PRODUCT INFORMATION

Product name: Anti-HER2 Affibody® imaging agent

Catalog number:

100 µg: 10.2046.01.0001

500 µg: 10.2046.01.0005

Source: Recombinant protein produced in *E. coli*.

Specificity: Affibody® Imaging Agent, Negative Control binds to a protein of bacterial origin. It does not bind to human HER2 or EGFR. Cross reactivity with other species has not been tested.

Mw: 6,8 kDa

Theoretical pI: 4.6

Purity: >95 % as determined by RP-HPLC analysis.

Applications: Small animal optical imaging.

Conjugation: The Affibody® molecule contains a unique C-terminal cysteine ideal for directed chemical modifications. However, tail-to-tail dimers are spontaneously generated via a disulfide bridge between the C-terminal cysteines. Prior to coupling via the C-terminal cysteine, the Affibody® molecule needs to be reduced to expose the reactive cysteine residue. Recommended reducing condition is 20 mM DTT at a pH above 7.5 and incubation at room temperature for 2 hours. Remove excess DTT by passage through a desalting column, not by dialysis.

Form: Lyophilized protein. Lyophilized from 10 mM NH₄HCO₃.

Storage: +4 °C is recommended for lyophilized protein. For reconstituted protein in physiological buffer, short-term storage at +4 °C is recommended. For long-term storage, the protein solution should be aliquoted and then stored at -20 °C.

Shipping: At ambient temperature.

Stability: There is no decrease in performance of the reconstituted Affibody® molecule (1 mg/ml in PBS) after 10 repeated freeze and thaw cycles or after storage for 2 weeks at room temperature.

Product support: www.affibody.com/shop
Affibody AB, Lindhagensgatan 133, SE-112 51 Stockholm, Sweden. Phone: +46-8-598 838 00, Fax: +46-8-598 838 01. E-mail: biotechnology@affibody.com.

LIMITATIONS

Warranty: Affibody® products are warranted to meet stated product specifications and to confirm to label descriptions when used and stored properly. Unless otherwise stated, this warranty is limited to one year from date of sales for products used, handled and stored according to Affibody AB's instructions. Affibody AB's sole liability is limited to replacement of the product or refund of the purchase price. Affibody® products are supplied for research use only. They are not intended for medicinal, diagnostic or therapeutic use. Affibody® products may not be resold, modified for resale or used to manufacture commercial products without prior written approval from Affibody AB.

AFFIBODY AB, Lindhagensgatan 133, SE-112 51 Stockholm, Sweden. Phone: +46-8-598 838 00, Fax: +46-8-598 838 01, E-mail: biotechnology@affibody.com, Web: www.affibody.com/shop.
Rev 100204